07 May 2024
07 May 2024
BI 764524 demonstrated to be well tolerated following intravitreal administration of single and multiple doses.
The transformative potential of decentralised clinical trials (DCTs) has been heralded in recent years.
The study aims to evaluate the pharmacokinetics, pharmacodynamics, and safety profile of NNC6022-0001.
The UK-based research team now hopes to develop a prototype for an implantable device.
Around 64 healthy adult participants will be enrolled across eight cohorts as part of the study.
The company expects to publish initial data from the trial later this year.
The study did not show a statistically significant improvement in overall survival after treatment with the uproleselan regimen.
The study will assess the drug's safety, tolerability, pharmacokinetics and pharmacodynamics in obstructive HCM patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
